Cortney Caudill Sells 8,857 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 8,857 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the transaction, the chief operating officer directly owned 7,055 shares of the company’s stock, valued at approximately $477,200.20. The trade was a 55.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Cortney Caudill also recently made the following trade(s):

• On Monday, March 9th, Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.80, for a total transaction of $1,356,000.00.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $66.48 on Thursday. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. The stock has a market capitalization of $7.85 billion, a PE ratio of 26.70, a P/E/G ratio of 0.27 and a beta of 0.98. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $82.22. The company has a fifty day moving average of $72.63 and a two-hundred day moving average of $70.64.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.26 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Benchmark raised their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Finally, TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $78.56.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC increased its holdings in shares of Halozyme Therapeutics by 1,554.7% during the 4th quarter. Corient Private Wealth LLC now owns 196,600 shares of the biopharmaceutical company’s stock worth $13,231,000 after buying an additional 184,719 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in Halozyme Therapeutics by 1,202.4% in the fourth quarter. Hsbc Holdings PLC now owns 82,323 shares of the biopharmaceutical company’s stock valued at $5,584,000 after acquiring an additional 76,002 shares during the last quarter. MidFirst Bank acquired a new stake in Halozyme Therapeutics during the fourth quarter worth $210,000. Pacer Advisors Inc. increased its stake in Halozyme Therapeutics by 95.7% during the fourth quarter. Pacer Advisors Inc. now owns 937,293 shares of the biopharmaceutical company’s stock worth $63,080,000 after acquiring an additional 458,419 shares during the last quarter. Finally, Caitlin John LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $465,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.